Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.37
Dollar change
+0.09
Percentage change
3.88
%
Index- P/E- EPS (ttm)-1.17 Insider Own35.97% Shs Outstand21.84M Perf Week2.16%
Market Cap55.60M Forward P/E- EPS next Y-0.96 Insider Trans0.60% Shs Float15.02M Perf Month-14.44%
Income-19.92M PEG- EPS next Q-0.18 Inst Own35.92% Short Float0.60% Perf Quarter-9.54%
Sales6.21M P/S8.95 EPS this Y7.32% Inst Trans-9.23% Short Ratio3.58 Perf Half Y-25.93%
Book/sh1.81 P/B1.31 EPS next Y-26.32% ROA-55.10% Short Interest0.09M Perf Year107.90%
Cash/sh1.66 P/C1.42 EPS next 5Y- ROE-70.01% 52W Range0.96 - 3.85 Perf YTD-15.65%
Dividend Est.- P/FCF- EPS past 5Y68.14% ROI-49.13% 52W High-38.44% Beta0.84
Dividend TTM- Quick Ratio6.99 Sales past 5Y17.21% Gross Margin29.12% 52W Low146.68% ATR (14)0.17
Dividend Ex-Date- Current Ratio7.34 EPS Y/Y TTM50.33% Oper. Margin-340.74% RSI (14)43.64 Volatility9.02% 6.86%
Employees66 Debt/Eq0.04 Sales Y/Y TTM20.00% Profit Margin-320.97% Recom1.00 Target Price4.85
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q58.96% Payout- Rel Volume2.32 Prev Close2.28
Sales Surprise8.34% EPS Surprise17.95% Sales Q/Q71.64% EarningsMar 06 BMO Avg Volume25.36K Price2.37
SMA20-3.33% SMA50-11.61% SMA200-17.76% Trades Volume58,883 Change3.88%
Date Action Analyst Rating Change Price Target Change
Jan-07-16Initiated Rodman & Renshaw Buy $4
Mar-13-15Downgrade Oppenheimer Outperform → Perform
Nov-26-13Initiated Oppenheimer Outperform $6
Mar-26-24 07:00AM
Mar-07-24 10:09AM
Mar-06-24 12:53PM
07:00AM
Feb-28-24 07:00AM
07:00AM Loading…
Feb-12-24 07:00AM
Feb-05-24 11:27AM
Jan-31-24 07:00AM
Jan-03-24 07:00AM
Dec-20-23 07:00AM
Nov-27-23 07:00AM
Nov-07-23 09:12AM
Nov-06-23 08:11AM
07:00AM
Nov-02-23 08:00AM
02:19PM Loading…
Nov-01-23 02:19PM
Oct-30-23 09:21AM
Oct-12-23 07:00AM
Oct-03-23 07:00AM
Aug-31-23 08:00AM
Aug-08-23 07:00AM
Jul-25-23 08:00AM
Jun-26-23 08:00AM
May-18-23 08:00AM
May-16-23 07:00AM
May-15-23 08:00AM
May-12-23 04:05PM
May-05-23 08:00AM
May-01-23 08:00AM
Apr-27-23 08:00AM
07:00AM Loading…
Mar-30-23 07:00AM
Mar-20-23 08:00AM
Mar-02-23 08:00AM
Feb-14-23 08:00AM
Nov-28-22 08:00AM
Nov-15-22 04:05PM
Nov-08-22 07:00AM
Oct-25-22 08:00AM
Sep-13-22 04:05PM
Sep-08-22 09:00AM
Aug-09-22 07:00AM
Aug-02-22 08:00AM
Jul-14-22 08:00AM
Jun-09-22 08:00AM
Jun-02-22 08:00AM
May-10-22 07:30AM
Apr-28-22 07:30AM
Mar-16-22 04:05PM
Mar-08-22 07:30AM
Feb-28-22 07:00AM
Feb-22-22 04:30PM
Feb-15-22 08:00AM
Jan-27-22 08:00AM
Jan-18-22 08:11AM
Nov-22-21 06:02AM
Nov-09-21 07:30AM
Nov-03-21 04:05PM
Oct-26-21 08:30AM
Oct-13-21 08:30AM
Aug-10-21 07:00AM
Aug-04-21 08:30AM
Jul-23-21 08:30AM
Jun-02-21 08:04AM
May-27-21 08:00AM
May-24-21 05:07AM
May-21-21 08:30AM
May-14-21 06:00AM
May-12-21 06:00AM
May-11-21 06:30AM
06:00AM
May-10-21 04:05PM
May-06-21 06:00AM
May-04-21 04:15PM
Apr-29-21 06:00AM
Apr-19-21 06:00AM
Apr-15-21 07:49AM
Apr-14-21 04:05PM
Mar-22-21 07:53AM
Mar-09-21 06:30AM
05:30AM
Mar-08-21 10:11AM
Mar-02-21 06:00AM
Feb-24-21 06:00AM
Feb-09-21 06:00AM
Feb-08-21 04:05PM
Feb-04-21 08:30AM
Feb-03-21 08:32AM
Jan-26-21 06:30AM
Nov-29-20 02:33PM
Nov-11-20 07:14AM
Nov-09-20 06:30AM
Nov-03-20 07:53AM
06:30AM
Nov-02-20 06:30AM
Oct-13-20 06:30AM
Oct-06-20 06:30AM
Sep-10-20 06:30AM
Sep-08-20 06:30AM
Sep-03-20 06:30AM
Aug-31-20 05:00PM
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROUBIN GARY SDirectorNov 30 '23Buy2.5350,000126,540438,902Dec 04 04:15 PM
Stuka PaulDirectorMay 12 '23Buy1.63175,000285,722248,534May 16 04:16 PM
BERMAN MICHAELDirectorMay 12 '23Buy1.63122,497200,001122,497May 16 04:15 PM
ROUBIN GARY SDirectorMay 12 '23Buy1.6361,249100,001233,545May 16 04:15 PM
Kester Thomas JDirectorMay 12 '23Buy1.6361,249100,001108,590May 16 04:16 PM